Riad Sherif
Tracked across 3 events · 31 articles · First seen May 29, 2026 · Last active Jun 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Oculis announced an upcoming presentation at Clinical Trials at the Summit 2026, where its CEO, Riad Sherif, will highlight the development journey of Privosegtor. Privosegtor is a novel peptoid small molecule with the potential to…
Impact: Riad Sherif, as CEO of Oculis, is the presenter of the Privosegtor program, emphasizing the company's strategic direction and the potential of the drug.
Jun 11, 2026 · 7 articles
Business
Oculis announced disappointing topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 eye drops in patients with diabetic macular edema (DME). The primary endpoint of improved best corrected visual acuity was not…
Impact: As CEO of Oculis, Riad Sherif announced the disappointing Phase 3 trial results for OCS-01 and outlined the company's strategic shift to focus on other late-stage development programs.
May 29, 2026 · 18 articles
Business
Oculis, a global biopharmaceutical company, announced its management's participation in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9, 2026, in Miami, FL. Dr. Riad Sherif, CEO of Oculis,…
Impact: Dr. Riad Sherif, CEO of Oculis, will be the presenter at the fireside chat, representing the company.
Jun 08, 2026 · 6 articles
95
Riad Sherif presented programOculis Presents...
80
Riad Sherif claimed product worksOculis OCS-01 DME trial fails
80
Riad Sherif will presentOculis to Present at...
NEWSDESK
Track Riad Sherif live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard